Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.
Routine in vitro screening of a new synthetic series of 3,5-substituted 2-methylisoxazolidines revealed that three imidazole analogs (PR 967-248, PR 967-234, and PR 969-566) and, to a lesser extent, a triazole analog (PR 988-399) exerted rather potent antifungal activity against three systemic and four dermatophytic classes of fungi. When tested in vivo for ability to eradicate Candida vaginitis in the rat, the triazole derivative, PR 988-399, was effective after oral administration. In this in vivo test for efficacy, PR 967-234 and PR 969-566 reduced but did not eradicate the infection, while PR 967-248 was inactive. PR 988-399 was, moreover, 4- to 13-fold less potent than the three imidazoles in inhibiting testosterone synthesis in isolated rat Leydig cells. After oral or intravenous administration, PR 988-399 and PR 969-566 elicited the fewest cardiovascular and behavioural side effects in conscious dogs. The rat safety study consisted of oral dosing followed by evaluation of the exploratory motor activity of the naive animals in a novel environment. Motor activity was suppressed least by PR 988-399 and most by PR 969-566. In a battery of mouse behavioural-neuromuscular-drug interaction tests, PR 988-399 and PR 969-566 produced the fewest central-behavioural-neuromuscular signs. These efficacy-safety evaluations were performed with ketoconazole as a positive reference standard. The sequence of drug testing with respect to efficacy-safety considerations appears to be a suitable approach for early detection of orally active antifungal agents such as PR 988-399 for more advanced development.
Divisional Research and Development, Fisons Pharmaceuticals, Rochester, New York 14623.
G C
GC
Palmer
M J
MJ
Ordy
R D
RD
Simmons
J C
JC
Strand
L A
LA
Radov
G B
GB
Mullen
C R
CR
Kinsolving
V
V
St Georgiev
J T
JT
Mitchell
S D
SD
Allen
D000284:Administration, Oral; D000700:Analgesics; D000818:Animals; D000927:Anticonvulsants; D000935:Antifungal Agents / Q000138:chemical synthesis / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D007555:Isoxazoles / Q000138:chemical synthesis / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009422:Nervous System Diseases / Q000139:chemically induced / Q000503:physiopathology; D010080:Oxazoles / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship
D000700:Analgesics; D000927:Anticonvulsants; D000935:Antifungal Agents; D007555:Isoxazoles; D010080:Oxazoles